Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
These recommendations update information regarding the polysaccharide vaccine licensed in the United States for use against disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, as well as antimicrobial agents for chemoprophylaxis against meningococcal disease (superseding MMWR 1985;34:255-9). This report provides additional information regarding meningococcal vaccines and the addition of ciprofloxacin and ceftriaxone as acceptable alternatives to rifampin for chemoprophylaxis in selected populations.
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D002443:Ceftriaxone / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000627:therapeutic use; D000075202:Contraindications; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D009345:Neisseria meningitidis / Q000276:immunology*; D012293:Rifampin / Q000627:therapeutic use; D014611:Vaccination / Q000592:standards*
D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D002939:Ciprofloxacin; D002443:Ceftriaxone; D012293:Rifampin